22 related articles for article (PubMed ID: 26269158)
1. Serum methionine metabolites are risk factors for metastatic prostate cancer progression.
Stabler S; Koyama T; Zhao Z; Martinez-Ferrer M; Allen RH; Luka Z; Loukachevitch LV; Clark PE; Wagner C; Bhowmick NA
PLoS One; 2011; 6(8):e22486. PubMed ID: 21853037
[TBL] [Abstract][Full Text] [Related]
2. The Effect of an Information Support Program on Self-Efficacy of Prostate Cancer Patients during Hormonal Therapy.
Yang R; Lu Z; Gu X; Dai B
Asia Pac J Oncol Nurs; 2021; 8(6):639-652. PubMed ID: 34790848
[TBL] [Abstract][Full Text] [Related]
3. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
4. Risk factors of positive surgical margin and biochemical recurrence of patients treated with radical prostatectomy: a single-center 10-year report.
Li K; Li H; Yang Y; Ian LH; Pun WH; Ho SF
Chin Med J (Engl); 2011 Apr; 124(7):1001-5. PubMed ID: 21542957
[TBL] [Abstract][Full Text] [Related]
5. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
6. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
7. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
8. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
[TBL] [Abstract][Full Text] [Related]
9. Long-term oncological outcomes after laparoscopic radical prostatectomy.
Hruza M; Bermejo JL; Flinspach B; Schulze M; Teber D; Rumpelt HJ; Rassweiler JJ
BJU Int; 2013 Feb; 111(2):271-80. PubMed ID: 22757970
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of lymphovascular invasion in radical prostatectomy specimens.
Ng J; Mahmud A; Bass B; Brundage M
BJU Int; 2012 Nov; 110(10):1507-14. PubMed ID: 22502733
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of biochemical recurrence following radical prostatectomy].
Dai B; Chang K; Kong Y; Qu Y; Wang Y; Jia Z; Ye D; Wang C; Zhang H; Yang W
Zhonghua Wai Ke Za Zhi; 2015 Apr; 53(4):261-5. PubMed ID: 26269158
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]